Industry Insights
The report encompasses the forecast as well as analysis of the AI in the Drug Discovery market on a global and regional level. The study displays historical data of 2016 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Million). Additionally, the market growth drivers, opportunities, restraints, and trends are also included in the AI in the Drug Discovery market report.
We have encompassed industry analysis models in our report and extensively demonstrated the key business strategies and competitive landscape of the AI in the Drug Discovery market in our study.
Our study also includes an analysis of Porter’s Five Forces framework for understanding the competitive strategies used by market competitors. It also encompasses PESTLE analysis and SWOT analysis.
The report also offers an in-depth analysis of the market share of each industry player and gives an outline of the market position of key players in the AI in the Drug Discovery market. Moreover, the study offers wide coverage of key strategic improvements witnessed in the market such as acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, R&D activities, and geographical expansion of key players of the AI in Drug Discovery market.
The study provides a decisive view of the AI in the Drug Discovery market by segmenting the AI in the Drug Discovery market based on drug type, technology, end-user, therapeutic area, and regions. All the segments and sub-segments have been examined based on historic, current and future trends in the global market and the market size is estimated from 2020 to 2026 in terms of value. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
An AI in Drug Discovery is used to identify targets, in silico drug design, drug development, predictive analytics, research risk assessment, clinical tracking and even more.
Machine learning may help maximize treatment by combining biological and clinical evidence with mathematical models and can be used to develop drug testing and probabilistic treatment applications. Computational deep learning research indicates this methodology should be helpful in finding complex models in results. Since biological and clinical data are diverse, deterministic quantic machine learning algorithms offer a reasonable opportunity to advance interpret them. However, one of the major challenges in the drug discovery phase is patient health.
The global AI in the Drug Discovery market is segmented into drug type, technology, end-user, therapeutic area, and region. On the basis of drug type, the global AI in the Drug Discovery market is classified as a small molecule and large molecule. The small molecule segment is expected to record the fastest growth over the predictable period, due to its advantages over the large molecule. On the basis of technology, the global AI in the Drug Discovery market is bifurcated into deep learning, machine learning and others where machine learning is more dominating over the predictable period. On the basis of end-user, the global AI in the Drug Discovery market is divided into pharmaceutical companies, biopharmaceutical companies, academic, and research institutes and others where pharmaceutical companies are leading. The global AI in the Drug Discovery industry is categorized into metabolic diseases, cardiovascular diseases, immuno-oncology, neurodegenerative diseases and others where oncology is at the front, depending on therapeutic areas.
Key players operating in the AI in the Drug Discovery industry are Atomwise Inc, BenevolentAI, Bio age, Cloud Pharmaceuticals Inc, Exscientia Ltd, Insilico Medicine Inc, Numerate Inc, Envisagenics Inc, Two XAR Inc, Accutar Biotechnology Inc, Recursion Pharmaceuticals Inc, Silicon Therapeutics LLC, AstraZeneca PLC.
This report segments the AI in Drug Discovery market as follows:
Global AI in Drug Discovery Market: By Drug Type Segment Analysis
- small molecule
- large molecule
Global AI in Drug Discovery Market: By Technology Segment Analysis
- deep learning
- machine learning
- other segments
Global AI in Drug Discovery Market: By End-user Segment Analysis
- pharmaceutical companies
- biopharmaceutical companies
- academic and research institutions
Global AI in Drug Discovery Market: By Therapeutic Area Segment Analysis
- metabolic disease
- cardiovascular disease
- immuno-oncology
- oncology
- neurodegenerative diseases
Global AI in Drug Discovery Market: Regional Segment Analysis
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-East Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- The Middle-East and Africa
- GCC Countries
- South Africa
- Rest of Middle-East Africa
Key Pointers Addressed by the Report
- Historical data and forecast analysis of the market
- Drivers and Restraints affecting market dynamics
- Exhaustive analysis about the future market trends
- Comprehensive information about the leading market segments and regions
- Potential opportunities for the players in the market
- Business strategies by the major players operating in the global market
- Strategic developments made by the competitive players and in-depth analysis about its impact on market growth
Table of Content
Key Insights from Primary Research
- According to our primary respondents, we have analyzed that the global AI in the Drug Discovery market is anticipated to grow annually with a CAGR of nearly 39% till 2026 end.
- It was established through primary research that the global AI in the Drug Discovery market was valued at around USD 830 million in 2019.
- On the basis of drug type, the small molecule led the market in 2019 accounting for around 60% share, in 2019
- Based on technology, the machine learning segment held the largest share in the global AI in the Drug Discovery market, accounted for approximately 50% share in the global market in 2019.
- By the end-user, the pharmaceutical companies segment held a major share in the global AI in the Drug Discovery market in 2019 and is projected to maintain a similar trend over the forecasted period.
- On the basis of therapeutic area segmentation, the oncology category held the leading share of around 25% in 2019.
- On the basis of region segmentation, the North America region held the leading share of around 50% in 2019.
Key Recommendations from Analysts
- Our analysts predict that the global AI in the Drug Discovery market is probable to reach a market value of USD 12,000 million in 2026 and was valued at around USD 830 Million in 2019.
- Drug companies rapidly understand the importance of introducing systems focused on Artificial Intelligence (AI) that can exploit data on gene variants, receptor targets, metabolic enzymes, disease events, and clinical studies to find hidden associations in drug-disease, this is a key factor in fueling the market growth globally.
- By therapeutic area type, the oncology segment is anticipated to grow at a rate of around 4 % over the projected period, due to soaring growth in the oncology treatment.
- Our analysts anticipate that the market to witness the fastest growth between 2023-2026 is the North American region due to the rise in spending on using Artificial Intelligence. This growing investment by pharmaceuticals companies is expected to drive the global AI in the Drug Discovery market.
Market Attractiveness-By Therapeutic Area
Industry Major Market Players
- Atomwise Inc
- BenevolentAI
- Bio age
- Cloud Pharmaceuticals Inc
- Exscientia Ltd
- Insilico Medicine Inc
- Numerate Inc
- Envisagenics Inc
- Two XAR Inc
- Accutar Biotechnology Inc
- Recursion Pharmaceuticals Inc
- Silicon Therapeutics LLC
- AstraZeneca PLC.
Safe and Secure SSL Encrypted
Choose License Type
HAVE A QUESTION? Executive will help you find what you are looking for.
REQUEST CUSTOMIZATION
Still haven't found what you're looking for? Speak to our Custom Research Team
Learn More